Authors: Abdul Manan Shaikh, Azizullah Jalbani, Saeed Ahmed Sangi, Barkat Ali Shaikh, Zafar Ali Pirzada, Abdul Latif Jokhio
Abstract
Coronary heart disease is a medical emergency most often caused by occlusive coronary thrombus. Approximately 30% of patients with coronary heart disease die, one half of them within the first hour of symptom onset. Mortality can be significantly reduced by rapid management. Heparin is injectable rapidly acting anticoagulant. Aim of present study was to evaluate the effect of low molecular weight heparin (LMWH) and unfractionated heparin specifically in patients with coronary heart disease and to compare the effects of low molecular weight heparin with unfractionated heparin and identify the best of either type of heparin. Types Of Study: This study was designed on 60 patients arranged in two groups i.e., group A and group B. Each group containing equal number of patients. Patients were collected from National Institute of Cardiovascular Diseases (NICVD) and respected study was followed in the Department of Pharmacology and Therapeutics, BMSI, JPMC, Karachi, for the period of three months. Either patient received 1 mg of Enoxaparin (LMWH) per kg body weight administered subcutaneously twice daily or continues I/V unfractionated heparin. Therapy was continued for minimum 48 hours to a maximum for 8 to 10 days and follow-up data was collected on important coronary endpoints such as hemorrhage, myocardial infarction, recurrent angina and death, over a period of 90
days. Results: Incidence of recurrence in group A - myocardial infarction with low molecular weight heparin, heamorrhage observed in 6 (20%) patients and in group B – myocardial infarction with unfractioned heparin, hemorrhage observed in 15 (50%) patients. Similarly, incidence of re-infarction in group A, found in 8 (26%) patients and in group B, it was found in 17 (56%) patients. Similarly, incidence of recurrent angina in group A, observed in 8 (26%) patients and in group B, it was observed in 17 (56%) patients. Similarly, incidence of death occurred in 5 (16.6%) patients and in group B, incidence of death occurred in 14 (46.6%) patients. When compared between group A and B, more incidence of complications are observed in group B than group A. Conclusion: Results of this study showed that low molecular weight heparin is more
effective in comparison with unfractionated heparin, as it is easy to administer, does not
require any monitoring as required in unfractionated heparin. Low molecular weight
heparin has fewer side effects. The safety and efficacy of low molecular weight heparin
is better than that of unfractionated heparin in conornary heart disease patients.
Keywords: LMWH = Low molecular weight heparin UFH = Unfractionated heparin
